Department of Pathobiology, School of Veterinary Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, United States of America.
Host-Pathogen Interactions, Texas Biomedical Research Institute, San Antonio, Texas, United States of America.
PLoS Pathog. 2023 Aug 16;19(8):e1011595. doi: 10.1371/journal.ppat.1011595. eCollection 2023 Aug.
Ebola (EBOV) and Marburg viruses (MARV) cause severe hemorrhagic fever associated with high mortality rates in humans. A better understanding of filovirus-host interactions that regulate the EBOV and MARV lifecycles can provide biological and mechanistic insight critical for therapeutic development. EBOV glycoprotein (eGP) and MARV glycoprotein (mGP) mediate entry into host cells primarily by actin-dependent macropinocytosis. Here, we identified actin-binding cytoskeletal crosslinking proteins filamin A (FLNa) and B (FLNb) as important regulators of both EBOV and MARV entry. We found that entry of pseudotype psVSV-RFP-eGP, infectious recombinant rVSV-eGP-mCherry, and live authentic EBOV and MARV was inhibited in filamin A knockdown (FLNaKD) cells, but was surprisingly enhanced in filamin B knockdown (FLNbKD) cells. Mechanistically, our findings suggest that differential regulation of macropinocytosis by FLNa and FLNb likely contributes to their specific effects on EBOV and MARV entry. This study is the first to identify the filamin family of proteins as regulators of EBOV and MARV entry. These findings may provide insight into the development of new countermeasures to prevent EBOV and MARV infections.
埃博拉病毒(EBOV)和马尔堡病毒(MARV)可引起人类严重的出血热,并伴有高死亡率。更好地了解调节 EBOV 和 MARV 生命周期的丝状病毒与宿主的相互作用,可以为治疗性开发提供关键的生物学和机制见解。埃博拉病毒糖蛋白(eGP)和马尔堡病毒糖蛋白(mGP)主要通过肌动蛋白依赖性胞吞作用介导进入宿主细胞。在这里,我们确定肌动蛋白结合细胞骨架交联蛋白细丝蛋白 A(FLNa)和 B(FLNb)是 EBOV 和 MARV 进入的重要调节剂。我们发现,假型 psVSV-RFP-eGP、感染性重组 rVSV-eGP-mCherry 和活的真实 EBOV 和 MARV 的进入在细丝蛋白 A 敲低(FLNaKD)细胞中被抑制,但在细丝蛋白 B 敲低(FLNbKD)细胞中出乎意料地增强。从机制上讲,我们的研究结果表明,FLNa 和 FLNb 对胞吞作用的差异调节可能有助于它们对 EBOV 和 MARV 进入的特定影响。这项研究首次确定细丝蛋白家族蛋白是 EBOV 和 MARV 进入的调节剂。这些发现可能为开发预防 EBOV 和 MARV 感染的新对策提供思路。